Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lei Li
With
National Institutes for Food and Drug Control, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
* Primary objective: To establish a HRD status reference standard based on WGS.
* Secondary objective: To validate the analytical performance of panel HRD status using WGS HRD status as reference standard.
* Exploratory objective 1: To explore how methylation of selective genes correlate with WGS HRD status and efficacy.
* Exploratory objective 2: To explore how HRR gene mutations correlate with WGS HRD status and efficacy.
* Exploratory objective 3: To set up a harmonized bioinformatic analysis workflow for WGS HRD status.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age at diagnosis
Ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
High-grade serous or high-grade endometroid histological type
FIGO stage II, III, or IV
Complete response or partial response following completion of first-line adjuvant chemotherapy
PARPi administered as first-line maintenance therapy
You may not be if
First-line surgery not conducted
Total round of first-line chemotherapy (neoadjuvant and adjuvant) less than 5
First-line PARPi maintenance therapy initiated beyond 12 weeks after last dose of chemotherapy
